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Metabolic syndromeMedium-chain triglycerides (MCT) are widely applied in the treatment of long-chain fatty acid oxidation disor-
ders. Previously itwas shown that long-termMCT supplementation strongly affects lipidmetabolism inmice.We
here investigate sex-speciﬁc effects in mice with very-long-chain-acyl-CoA dehydrogenase (VLCAD) deﬁciency
in response to a long-term MCT modiﬁed diet. We quantiﬁed blood lipids, acylcarnitines, glucose, insulin and
free fatty acids, as well as tissue triglycerides in the liver and skeletal muscle under a control and an MCT diet
over 1 year. In addition, visceral and hepatic fat content and muscular intramyocellular lipids (IMCL) were
assessed by in vivo 1H magnetic resonance spectroscopy (MRS) techniques. The long-term application of an
MCT diet induced a marked alteration of glucose homeostasis. However, only VLCAD−/− female mice developed a
severe metabolic syndrome characterized by marked insulin resistance, dyslipidemia, severe hepatic and visceral
steatosis, whereas VLCAD−/−males seemed to be protected and only presented with milder insulin resistance.
Moreover, the highly saturated MCT diet is associated with a decreased hepatic stearoyl-CoA desaturase 1 (SCD1)
activity in females aggravating the harmful effects of a saturatedMCT diet. Long-termMCT supplementation deeply
affects lipidmetabolism in a sexual dimorphicmanner resulting in a severemetabolic syndromeonly in femalemice.
These ﬁndings are striking since the ﬁrst signs of insulin resistance already occur in female VLCAD−/−mice during
their reproductive period. How thesemetabolic adaptations are ﬁnally regulated needs to be determined. More im-
portant, the relevance of these ﬁndings for humans under these dietary modiﬁcations needs to be investigated.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Lipidmetabolism is differently regulated between the sexes resulting
in various phenotypes with regard to body composition, body fat distri-
bution and substrate metabolism. It is known that lipid metabolism and
expression of genes coding for fatty acid oxidation (FAO) enzymes are
regulated by different means such as dietary fatty acids [1] or the tran-
scription factor peroxisome proliferator-activated receptor α (PPARα).
In addition, sex hormones do play an important role and determine reg-
ulation in a sexually dimorphic manner [2,3]. Therefore, the degree of
disturbance in fatty acid metabolism and lipid homeostasis as they
occur in inherited fatty acid oxidation disorders (FAOD) may also be
strongly gender-speciﬁc.
FAOD are a group of diseases comprising defective enzymes of the
mitochondrialβ-oxidation [4]. Symptoms occurmainly during cataboliciatrics, Center for Pediatrics and
strasse 1, D-79106 Freiburg,
270.
cci).situations such as prolonged fasting or illnesses presenting with
hypoketotic hypoglycemia, hepatic encephalopathy, cardiomyopathy
and skeletal myopathy [5]. Very long-chain acyl-CoA dehydrogenase
deﬁciency (VLCADD) is considered the most common defect of the mi-
tochondrial oxidation of long-chain fatty acids with an incidence of
1:50,000–1:100,000 [5–7]. VLCADD is characterized by different clinical
phenotypes aswell as severity and age at onset [8,9]. The recommended
therapeutical approach includes the replacement of long-chain triglyc-
erides by medium-chain triaglycerides (MCT), which can be fully oxi-
dized in the mitochondrial β-oxidation. The clinical efﬁcacy of MCT is
widely recognized especially with respect to the prevention and treat-
ment of cardiomyopathy and muscular symptoms [10,11]. Although
an MCT diet is considered a safe dietary intervention and is applied in
different FAOD for longer periods of time, recent reports highlight the
adverse effects of an MCT diet in the murine model of VLCADD
[12–16]. Long-term supplementation over one year contributed to the
development of an unexpected clinical phenotype with an increased
body fat content and a disturbance in body fat composition in the
mouse model of VLCADD [13,16]. Because of these signiﬁcant changes
due to dietary interventions in the VLCADmouse, we here assessed pos-
sible additional sex-speciﬁc effects.
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free fatty acids were measured, while the concentration of triglycerides
(TAGs) was assessed in the liver and skeletal muscle of WT and
VLCAD−/− mice under a control diet and after MCT supplementation.
Acylcarnitine proﬁles were analyzed in dried blood spots to evaluate
the metabolic state of WT and VLCAD−/− mice. Visceral and hepatic
fat as well as the muscular IMCL content were assessed by in vivo 1H
(MR) techniques.
2. Materials and methods
2.1. Animals
Experiments were performed on the fourth- to ﬁfth-generation in-
tercrosses of C57BL6+129sv VLCAD genotypes. Littermates served as
controls and genotyping ofmicewas performed as described previously
in Exil et al. [17]. Serum parameters were determined under standard
conditions and blood was taken 5 h after food intake at the age of six
months. Mice at the age of 12 months were sacriﬁced immediately
after MR investigation by CO2 asphyxiation.
Blood samples were collected by heart puncture. Serumwas obtain-
ed by centrifugation at 16,000 g for 10min and stored at−80 °C for fur-
ther analysis. The liver and skeletal muscle were rapidly removed and
immediately frozen in liquid nitrogen. The right anterior and medial
lobes of the liver with the gall bladder were transferred in 10% formal-
dehyde for histopathology.
All animal studies were performed with the approval of the
University's Institutional Animal Care and Use Committee and in accor-
dance with the Committees' (LANUV) guidelines.
2.2. Diet composition and supplementation
At 5weeks of age,mice of each genotypewere divided in two groups
and fed with different diets for one year. The ﬁrst group received a nor-
mal puriﬁedmouse diet containing 5% crude fat in the form of LCT, cor-
responding to 12% of metabolizable energy as calculated with Atwater
factors (ssniff® EF R/M Control, ssniff Spezialdiäten GmbH, Soest,
Germany). The second group was fed with a diet corresponding as
well to 12% of total metabolizable energy. Here, 4.4% from a total of 5%
fat was MCT (Ceres®MCT-oil, basis GmbH, Oberpfaffenhofen,
Germany) while the remaining 0.6% was derived from soybean oil pro-
viding the required essential long-chain fatty acids. The necessary
amount of essential long-chain fatty acids was calculated in accordance
to the Nutrient Requirements of Laboratory Animals (Subcommittee on
Laboratory Animal Nutrition, Committee on Animal Nutrition, Board on
Agriculture, National Research Council). Both diets based on puriﬁed
feed ingredients contained the same nutrient concentration as follows:
94.8% drymatter, 17.8% crude protein (N × 6.25), 5% crude fat, 5% crude
ﬁber, 5.3% crude ash, 61.9% nitrogen free extract, 36.8% starch, 14.8%
dextrin and 11% sugar. The detailed fatty acid composition of the diets
was previously reported [13]. In both diets the carbohydrate and pro-
tein contents corresponded to 69% and 19% ofmetabolizable energy, re-
spectively. All mouse groups received water ad libitum.
2.3. Magnetic resonance imaging (MRI)
2.3.1. General setup
Data were recorded on a Bruker AvanceIII 9.4 Tesla Wide Bore
(89 mm) nuclear magnetic resonance (MR) spectrometer operating at
frequencies of 400.13 MHz for 1H as previously described [13,18].
2.3.2. Intra- and extramyocellular lipids (IMCL and EMCL)
The mice were positioned on their left side within the animal han-
dling system and the right hind leg was ﬁxed in a 10-mm saddle coil
with the Tibialis anterior (TA) muscle aligned along the main magnetic
ﬁeld direction ensuring maximal spectral separation of IMCL andEMCL resonances [19]. Image acquisition and IMCL quantiﬁcation have
been performed as previously described [20].
2.4. Histological evaluation
Liver tissue was excised from the eviscerated animals and ﬁxed in
10% formalin. For light microscopy examination, the tissues were em-
bedded in parafﬁn and sectioned at 5 μm. Liver slices of all analyzed
mice were evaluated with a magniﬁcation of ×33 and stained with he-
matoxylin and eosin (H&E) for assessment of steatosis, inﬂammation,
and necrosis or Sirius red for assessment of ﬁbrosis. To determine lipid
content, 10 μm thick cryostat sections were collected on Superfrost
slides, and stained with Sudan III. Steatosis, degree of inﬂammation
and stage of ﬁbrosis were assessed as previously described [13,21].
2.5. Liver homogenate, triglyceride (TAG) and lipid peroxide content
Tissues were homogenized in CelLytic MT Buffer (Sigma-Aldrich,
Steinheim, Germany) in the presence of 1mg·mL−1 protease inhibitors
and centrifuged at 4 °C and 16,000 g for 10 min to pelletize any cell de-
bris. The clear supernatantwas immediately used for the enzyme assays
or stored at−80 °C.
The concentration of thiobarbituric acid reactive substance (TBARS)
resulting from decomposition of lipid peroxide products was deter-
mined ﬂuorimetrically in serum and liver tissue as previously described
[14]. TAG concentrations were measured in the liver as duplicates by
using enzymatic kits (EnzyChrom triacylglyceride Assay Kit, BioTrend,
Cologne, Germany) following the manufacturer's instructions. Brieﬂy,
TAGs were extracted from the liver and the concentration was mea-
sured enzymatically. Extracted TAGs were hydrolyzed to free fatty
acids and glycerol. This reacted with a dye to generate a colored com-
pound visible at 570 nm (spectrophotometry) or at Ex/Em = 535/
587 nm (ﬂuorescence).
2.6. Analysis of serum variables and transaminases
Free fatty acid (FFA), TAG and lipoprotein concentrationsweremea-
sured as duplicates in serum samples as described previously [15]. Glu-
cose and ketone bodies were determined with a Precision Xceed blood
sugar meter (Abbott, Wiesbaden, Germany).
Insulinwasmeasured in duplicate by using the UltrasensitiveMouse
Insulin ELISA Kit (Mercodia AB, Uppsala Sweden). Oxidized low density
lipoproteins (ox-LDL) were quantiﬁed in duplicates by using the
Enzyme-linked Immunosorbent Assay Kit for ox-LDL (Hölzel
Diagnostika, Cologne, Germany). Aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) were determined at 37 °C accord-
ingly to the ICFF procedures [22,23]. Insulin resistance was calculated
by the homeostasis monitoring assessment (HOMA) formula [24]. The
homeostasis model assessment (HOMA) of insulin resistance index, as
described by Matthews et al. [24], is the most easily obtained measure-
ment of insulin resistance which can be used as a reliable surrogate
measure of in vivo insulin sensitivity since this method correctly differ-
entiated between insulin sensitivity and insulin resistance [25]. HOMA
index was calculated with glucose and insulin concentrations obtained
after 5 h of fasting using the following formula: fasting blood glucose
(md/dL) × fasting insulin (μU/mL) / 22.5.
2.7. Analysis of acylcarnitines
Analysis of acylcarnitines was performed as described previously
[26–28]. Brieﬂy, acylcarnitines were extracted from dried blood spots
and tissues with acetonitrile/water (80/20% v/v) in the presence of
[2H3] free carnitine, [2H3] octanoyl-carnitine and [2H3] palmitoyl-
carnitine as internal standards. The extracted supernatant was dried
and the butylated acylcarnitines were analyzed by electron spray
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C18 acylcarnitines (saturated and unsaturated) were measured.
2.8. Statistical analysis
MRI data are reported asmean values± standard deviation (SD). All
other reported data are presented as means ± standard error of the
mean (SEM). n denotes the number of animals tested. Analysis for the
signiﬁcance of differences was performed using Student's t-tests for
paired and unpaired data. To test the effects of the variables, diet, geno-
type and sex two-way analysis of variance (ANOVA) with Bonferroni
post-test was performed (GraphPad Prism 5.0, GraphPad Software,
San Diego, California, USA). Differences were considered signiﬁcant if
p b 0.05.
3. Results
3.1. Clinical phenotype
As shown in Table 1, six month-old VLCAD−/− mice of both sexes
showed signiﬁcantly higher mean body weights compared to the WT
group under normal LCT mouse diet. Interestingly, mice upon an MCT
diet showed signiﬁcantly lower body weights compared to mice under
the LCT diet (p b 0.05), however, a signiﬁcantly increased liver/body
weight ratio was observed, which was especially evident in VLCAD−/−
female mice (Table 1) indicative of a signiﬁcant intrahepatic lipid
accumulation.
3.2. MCT diet severely affects glucose homeostasis
Since one year old VLCAD−/− mice under an MCT diet displayed a
phenotype similar to the metabolic syndrome [13], we tested whether
mutants develop sex speciﬁc insulin resistance already at the age of
six months and analyzed blood glucose and insulin concentration after
5 h of fasting.
As shown in Table 1, WT mice presented with sex speciﬁc differ-
ences in glucose an insulin concentration with respect to the genotype,
in that the glucose concentration was signiﬁcantly higher in VLCAD−/−
males as compared toWT under the dietary regimen. Moreover, female
VLCAD−/−mice showed signiﬁcantly lower concentrations of glucoseTable 1
Clinical parameters in VLCAD−/−mice either under control or MCT diet at the age of six month
signiﬁcant if p b 0.05 (Two way ANOVA and Student's t-test). * indicates signiﬁcant differences
indicates signiﬁcant differences between mice of the same sex but different genotypes under t
and phenotype under different dietary regimens.
LCT
WT VLCAD−/−
Male Female Male Fema
Clinical phenotype
Body weight [g] 27 ± 0.8 21.4 ± 1 30 ± 0.5# 23.2
Ratio liver/body weight [g/mg] 4.8 ± 0.07 4.3 ± 0.03* 5.1 ± 0.1 5.0
Serum variables
Glucose [mg/dL] 222 ± 11.4 240 ± 13.23 264 ± 17.5# 218.5
Insulin [pmol/L] 115.4 ± 29.3 105.9 ± 21.2 83.9 ± 17.4 76.5
HOMA index 9.1 ± 2.1 9 ± 1.8 9.1 ± 1.7 6
AST [U/L] 86.2 ± 5.7 83.2 ± 7.9 81.2 ± 9.3 87.6
ALT [U/L] 29.7 ± 3.6 20.0 ± 1.1* 19.6 ± 1.0 15.2
Serum lipids
FFA [μM] 319.4 ± 51.6 320.7 ± 50.6 369 ± 67.7 408.6
TAG [mg/dL] 57.5 ± 10.6 40.6 ± 7 92 ± 6.2# 70.3
Cholesterol total [mg/dL] 66.8 ± 11.5 72.8 ± 7.8 135.5 ± 13.9# 110
HDL [mg/dL] 55.5 ± 8.5 44.7 ± 8.3 75.8 ± 4 66.4
VLDL/LDL [mg/dL] 18.4 ± 2.7 11.4 ± 0.7* 30 ± 3# 32
ox-LDL [ng/mL] 611.8 ± 25.7 630.7 ± 25.7 605.2 ± 27.8 825.8and insulin as compared to males. Furthermore, we could observe an
overall high impact of the MCT diet on these parameters. Indeed, all
mice showed signiﬁcantly higher glucose and insulin concentrations
in all groups independent of sex and genotype. This effect was very
evident in females of both genotypes but it was especially striking in
VLCAD−/− females resulting in a markedly increased HOMA index. In
that, WT females supplemented with MCT displayed a two-fold higher
HOMA index as compared to WT females upon LCT diet (19.1 ± 3.2 vs
9 ± 1.8). This parameter was even higher in VLCAD−/− females
(22.2 ± 3.1 in VLCAD−/− females upon MCT vs 6 ± 1.4 in VLCAD−/−
females upon LCT) which was strongly suggestive of insulin resistance.
In contrast, males were not strongly affected as only VLCAD−/−males
upon MCT showed a signiﬁcantly higher HOMA index as compared to
mice of the same genotype upon LCT diet (Table 1).3.3. Alteration of blood lipids due to MCT supplementation
Blood lipid analysis revealed no sex speciﬁc but genotype dependent
differences upon LCT diet (Table 1). In accordance with previous data
[13,15], diet serum triacylglycerides (TAGs) and lipoprotein content
was signiﬁcantly higher in mutants as compared to WT littermates.
Sex-speciﬁc differences were only observed with respect to the highly
atherogenic ox-LDL. Already under this normal mouse diet VLCAD−/−
female mice were characterized by signiﬁcantly higher oxidized-LDL
(ox-LDL) lipoprotein levels (825.8 ± 42.3 vs 630.7 ± 27.8 ng/mL)
which have been recently associated with the development of metabol-
ic syndrome [29].
As shown in Table 1, MCT supplementation strongly affected lipo-
protein content in VLCAD−/− females with special regard to low-
density lipoproteins. Indeed, the concentration of VLDL/LDL was signi-
ﬁcantly higher as compared to VLCAD−/−males under the same dietary
regimen as well as the content of the atherogenic ox-LDL (1003.2 ±
25.4 vs 821.3 ± 35.7 ng/mL).3.4. Ectopic TAG increase in female VLCAD−/−mice under MCT diet
An ectopic TAG accumulation has been associated with insulin resis-
tance [30–32]. Therefore we tested whether a long-term MCT supple-
mentation induces a sex-speciﬁc accumulation of ectopic lipids.s. The values are mean ± SEM. (n= 6–8). Values denoted by *, # and § were considered
between male and female mice of the same genotype under the same dietary regimen. #
he same dietary regimen. § indicates signiﬁcant differences between mice of the same sex
MCT
WT VLCAD−/−
le Male Female Male Female
± 0.4# 25.6 ± 0.6 21.7 ± 0.4 26.5 ± 1§ 20.8 ± 0.6§
± 0.15 4.7 ± 0.18 4.6 ± 0.21 4.5 ± 0.09§ 5.3 ± 0.22*
± 8.85* 269 ± 18.61§ 296.5 ± 35.42*§ 282.5 ± 15.99 290 ± 29.13§
± 19.1* 123.7 ± 17.9 173.5 ± 25.8 179.1 ± 15.5§ 207 ± 20.8§
± 1.4 11.8 ± 2 19.1 ± 3.2§ 15.4 ± 1.6§ 22.2 ± 3.1§
± 10.2 110.6 ± 9.7 81.2 ± 6.0 140.5 ± 12.4§ 129.8 ± 19.33
± 1.2 22.8 ± 3.4§ 15.20 ± 1.2*§ 32.2 ± 1.4§ 26.2 ± 4.3§
± 51.2 436.2 ± 56.6§ 337.1 ± 42.1* 655.2 ± 87.7§ 709.2 ± 29.6#§
± 4.4*# 70.1 ± 9.7 66.6 ± 6.8§ 87.3 ± 6.3 87.6 ± 7.2§
± 2.4# 126 ± 9.8§ 111.7 ± 10§ 116.3 ± 1.7 133.2 ± 4.4*#§
± 3* 76.1 ± 6.2 63.6 ± 3.2 66.9 ± 2.8 64.8 ± 1.7
± 0.9# 29.6 ± 0.8§ 34.7 ± 0.7*§ 33.5 ± 0.9# 47.7 ± 2.3*#§
± 42.3*# 699.3 ± 67.6 898 ± 36.3*§ 821.3 ± 35.7§ 1003.2 ± 25.4*§
EC
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Fig. 1. Time-dependent triglyceride (TAG) and IMCL accumulation in the skeletalmuscle of female VLCAD−/−mice underMCT diet. A) and C) representmice at the age of 6months. B) and
D) representmice at the age of 12months. E) shows representative 1HMR spectra acquired from the Tibialis anteriormuscle ofWT and VLCAD−/−miceunderMCT (top) and LCT (bottom)
diet (Cho, choline; Cr, creatine; Tau, taurine). TAG concentration is expressed in μmol/mg tissue.White bars andblack bars representWTmice andVLCAD−/−mice, respectively. The values
are mean ± SEM (n= 6–8). LCT, long-chain triglycerides. MCT, medium-chain triglycerides. Values denoted by * and # were considered signiﬁcant if p b 0.05 (Two way ANOVA and
Student's t-test). * indicates signiﬁcant differences between genotypes under the same dietary regimen. # indicates signiﬁcant differences betweenmice of the same genotype under dif-
ferent dietary regimens.
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differences in the content of muscle TAG at the age of 6 months, as
shown in Fig. 1A. Six month-old female VLCAD−/− mice upon MCT,
however showed a signiﬁcantly higher TAG content as compared to
VLCAD−/− females under control diet (50 ± 10.5 vs 25.7 ±
8.5 μmol/mg). These data correlated with the accumulation of
intramyocellular (IMCL) lipids in the Tibialis anterior (TA)muscle. Char-
acteristic 1H MR spectra acquired in vivo for WT and VLCAD−/−mice at
the age of 12months fedwith either an LCT or anMCT diet are shown in
Fig. 1E. The spectra showed a very striking increase in signal intensity
for IMCL protons at 1.3 ppm, in both genotypes fed with MCT (top) as
compared to mice under normal diet (bottom). As shown in Fig. 1C,
quantiﬁcation of the spectra in 6 month-old females revealed a nearly
40% increase in IMCLunder theMCTdiet in both genotypes as compared
to the LCT diet indicating that the replacement of LCT byMCT may con-
tribute to the development of insulin resistance long-term [33].
Upon LCTVLCAD−/− females at the age of 12months displayed a sig-
niﬁcant increase in muscle TAG with a two-fold higher content ascompared to WT females at the same age (Fig. 1B). In accordance to
the data obtained in 6month-old VLCAD−/− females, a continuous sup-
plementation with an MCT diet over 12 months further increased mus-
cle TAG content up to 72.5 ± 14 μmol/mg. However, this increase was
not associated with a higher IMCL content since quantiﬁcation of spec-
tra showed no further accumulation in VLCAD−/− females. Of note,
IMCL content in VLCAD−/− females was two-fold higher as compared
to VLCAD−/− females under LCT diet at 12 months (Fig. 1D), whereas
MCT supplementation did not result in sex-speciﬁc differences with re-
spect to the IMCL content after this time period.
3.5. Altered fat distribution and fatty acid composition accompanied by he-
patic steatosis in VLCAD−/− females under MCT diet
Because of the increased muscular IMCL content suggestive of insu-
lin resistance, we analyzed the sex-speciﬁc effects of a prolonged MCT
diet on abdominal fat distribution and composition using in vivo 1H
MR imaging (MRI). Analysis of fat-only images in mice at the age of
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Fig. 2. Quantiﬁcation of abdominal fat distribution by 1H MRI. A) represents male and
B) represents female mice under either LCT or MCT diet. LCT, long-chain triglycerides.
MCT, medium-chain triglycerides. Values are expressed as fat per body volumemeasured
as % of measured volume. Values are mean ± SEM (n= 6–8). Values denoted by * and #
were considered signiﬁcant if p b 0.05 (Two way ANOVA and Student's t-test). * indicates
signiﬁcant differences betweenWT and VLCAD−/−mice under the same dietary regimen.
# indicates signiﬁcant differences betweenmice of the same genotype under different di-
etary regimens.
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males (Fig. 2A). In strong contrast, VLCAD−/− females under MCT diet
exhibited a signiﬁcantly higher overall fat content per measured body
volume (BV) as compared to WT mice under the same dietary regimen
(28.9 ± 3.1 vs 19.7 ± 5.2% BV; Fig. 2B). The classiﬁcation of abdominal
fat in visceral and deep/superﬁcial subcutaneous fat revealed a predom-
inant accumulation of visceral fat as compared tomutants upon the LCT
diet followed by alterations in subcutaneous fat to a minor extent. In
parallel, we observed a striking intrahepatic lipid accumulation upon
MCT as measured by in vivo 1H MRS (Fig. 3A). Indeed, VLCAD−/− fe-
males receiving MCT displayed a two-fold higher hepatic lipid content
as compared to VLCAD−/− females under the LCT diet. These ﬁndings
were conﬁrmed on liver histology with severe and diffuse
macrovesicular steatosis (grade 3) in VLCAD−/− females and accumula-
tion of large lipid droplets as shown in the representative picture of
Fig. 3B (right). In contrast, although a long-term MCT diet increased
the intrahepatic lipid content also in VLCAD−/−males, we observed in
only few cases cloudy swelling of hepatocytes with rarely
microvesicular vacuolization (Fig. 3B, right). Moreover, we observed a
positive correlation between serum thiobarbituric acid reactive sub-
stances (TBARS), serum cholesterol and visceral fat accumulation
which has been associated with the presence of metabolic syndrome
[51]. Indeed, as shown in Fig. 3C, the amount of visceral fat and the
serum TBARS:cholesterol ratio signiﬁcantly correlated (r2 = 0.5095;
p b 0.0001) and the highest ratio was detected in VLCAD−/− femalesupon MCT indicating that insulin resistance occurring already at the
age of 6 months degenerated into a metabolic defect strongly resem-
bling the human metabolic syndrome over time.
3.6. MCT supplementation contributes to the accumulation of long-chain
acylcarnitines in blood in mice at the age of one year
Acylcarnitines are considered a faithful parameter reﬂecting the efﬁ-
ciency of β-oxidation of fatty acids in providing the required energy.
Higher blood concentrations of acylcarnitines have been associated
with catabolic conditions and also with type 2 diabetes (T2D) [34]. In
contrast to previous reports [35–37], we did not observe a higher
acylcarnitine accumulation in male VLCAD−/− mice under LCT diet
(Fig. 4). However, this effect was evident whenmicewere supplement-
ed with MCT. Moreover, we observed a higher acylcarnitine concentra-
tion inmalemice probably due to the higher sex speciﬁcmusclemass in
males associated with the regulation of plasma carnitine and thereby
acylcarnitines by sex hormones [38] as already reported in adult female
rats [39]. Of interest was also the signiﬁcantly higher concentration of
the monounsaturated acylcarnitine species C16:1 (0.6 ± 0.01 vs
0.33 ± 0.03 μmol/L; p b 0.05) and C16 (2.56 ± 0.04 vs 1.6 ±
0.13 μmol/L; p b 0.05) in mutant males as compared to females under
the same dietary regimen (Fig. 4) (desaturation index: 0.291 vs 0.268;
p b 0.05). Whereas, the content of saturated C16:0 and C18:0
acylcarnitines was signiﬁcantly higher in VLCAD−/− female mice as
compared to VLCAD−/−males. Of interest, was the dramatic reduction
of C18:2 acylcarnitines in both genotypes of VLCAD−/− mice under
MCT diet as compared to mice under control diet.
4. Discussion
In this work, we demonstrate for the ﬁrst time that the long-term
application of dietaryMCTwithout increasing the total fat intake results
in a severe metabolic defect strongly resembling the human metabolic
syndrome over time in a sex speciﬁc manner. Indeed, female
VLCAD−/−mice present with marked insulin resistance, dyslipidemia,
abdominal obesity and steatohepatitis whereas VLCAD−/− males re-
main generally protected. The sex-speciﬁc response to the MCT diet is
also reﬂected by the accumulating acylcarnitine species which differ in
the degree of desaturation between male and female mice.
Ectopic lipid accumulation is a critical feature for the development of
insulin resistance [40–42]. In addition, the intramyocellular lipids
(IMCL) in the skeletal muscle are shown to play an important role in
this respect. Moreover, other factors such as fatty acid availability, up-
take and oxidation are crucial [43]. Because of the great bulk of reports
that link impaired fatty acid oxidation to insulin resistance [44–47] we
proposed that VLCAD−/− mice would develop a metabolic defect
strongly resembling the human metabolic syndrome. However, in ac-
cordance with a very recent report on patients with long-chain fatty
acid oxidation disorders [48], VLCAD−/−mice of both sexes did not dis-
play excessive accumulation of IMCL despite increased long-chain
acylcarnitines, increased serum TAG and lipoprotein concentrations. In
fact, we observed in both genotypes lower circulating insulin levels sug-
gesting either higher peripheral insulin sensitivity [47] or lower insulin
secretion. Only upon dietary modiﬁcation, female VLCAD−/−mice did
display a signiﬁcant increase in muscular IMCL as early as during their
reproductive period at the age of 6months associatedwith amarked in-
sulin resistance as demonstrated by the signiﬁcant increase in HOMA
index. These ﬁndings were also reﬂected by the high blood concentra-
tions of free fatty acids, the serum VLDL and ox-LDL proﬁle [29,49]. At
12 months of age a full metabolic defect strongly resembling the
human metabolic syndrome was observed in female VLCAD−/− mice
upon MCT with altered abdominal fat distribution and a massive in-
crease in visceral fat accompanied by steatohepatitis. This effect is likely
due to sex-speciﬁc differences in handling hepatic fatty acids resulting
in a more severe injury and systemic oxidative stress in females as a
*
#
§
§
§
§
MCT-VLCAD-/- male MCT-VLCAD-/- female
A
B
C
LCT-WT
MCT-WT
LCT-VLCAD-/-
MCT-VLCAD-/-
Fig. 3. Long-termMCT diet induces hepatic steatosis and systemic oxidative stress in VLCAD−/− femalemice. A) Relative contribution of lipid signals to the totalMR signal from non-water
suppressed 1HMR spectra of the liver (given in percent). B) Representative liver slices from one year old VLCAD−/−mice underMCT diet (×33). The degree of steatosiswas assessedwith
Sudan III. C) Positive correlation between serum thiobarbituric acid reactive substances (TBARS):total cholesterol ratio and visceral fat in WT and VLCAD−/−mice fed with either LCT or
MCT diet. LCT, long-chain triglycerides.MCT,medium-chain triglycerides. Values aremean±SEM (n=6–8). Values denoted by *, # and §were considered signiﬁcant if p b 0.05 (Twoway
ANOVA and Student's t-test). * indicates signiﬁcant differences betweenWT and VLCAD−/−mice under the same dietary regimen. # indicates signiﬁcant differences betweenmice of the
same genotype under different dietary regimens. § indicates signiﬁcant differences between sex but of the same genotype and under the same dietary regimen.
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tween visceral fat content and TBARS:cholesterol ratio as previously re-
ported [51–54]. Estrogens are known to protect against weight gain,
obesity and dyslipidemia [55], however, a decline in estrogen levels
after menopause or estrogen deﬁciency leads to a dysregulation of
lipid and energy metabolism inducing metabolic changes that expose
women to the same risk as men for the development of type 2 diabetes,
metabolic syndrome and cardiovascular diseases [56,57]. MCT induces
such metabolic dysregulation in VLCAD−/− female mice already during
their reproductive period. Our data therefore strongly suggest that
MCT indeed inhibits the likelihood protective effects of estrogens [50]
acting on sex-linked gene expression such as signaling pathways and
receptors.
Although congruent with the phenotype of a metabolic syndrome,
our ﬁndings are in contrast to published data on the sex dimorphism
in distribution of visceral fat in humans and the disposition to the devel-
opment of insulin resistance in rodents. In humans, men are prone toaccumulate visceral fat in the abdominal region, whereas pre-
menopausal women accumulatemore subcutaneous adipose tissue pri-
marily localized in peripheral body areas [58,59], however, a fat redistri-
bution occurs during and after menopause in response to sexual
hormones [60]. In addition, reports on rodents have demonstrated
that males are more prone to diet-induced obesity and insulin resis-
tance and display a lower glucose tolerance accompanied by a higher
expression of markers for oxidative stress [61–63]. An important obser-
vation of our study, however, is that the overall fatmetabolism seems to
be differently regulated in defects of mitochondrial β-oxidation
resulting in a sex-speciﬁc response to MCT supplementation.
It becomes very clear that the lowdesaturation degree of theMCTdiet
may play an important role in this context. This dietary effect is namely
associatedwith a lower hepatic stearoyl-CoAdesaturase 1 (SCD1) activity
in females [64]. This enzyme regulates the desaturation degree of the
total lipid fraction [65] and shows a hormonal regulation with higher ac-
tivity inmales [66]. These sex-speciﬁc differences are in our study clearly
AB
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#
#
# #
#
#
#
# #
#
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LCT-WT
MCT-WT
LCT-VLCAD-/-
MCT-VLCAD-/-
Fig. 4. Acylcarnitine proﬁles from dried blood spots of WT and VLCAD−/−mice fed with either LCT or MCT diet. LCT, long-chain triglycerides. MCT, medium-chain triglycerides. A) Male
mice. B) Female mice. Values are mean± SEM (n=6–8). Values denoted by * and #were considered signiﬁcant if p b 0.05 (Twoway ANOVA and Student's t-test). * indicates signiﬁcant
differences between WT and VLCAD−/−mice under the same dietary regimen. # indicates signiﬁcant differences between mice of the same genotype under different dietary regimens.
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serves as a marker of the mobilization of endogenous lipid stores.
Our ﬁndings were obtained in the VLCAD−/− mice and therefore
they do not allow a full extrapolation to the human VLCAD-deﬁciency.
However, many patients affected by defects of long-chain fatty
acid oxidation are supplemented with MCT from the time of diagno-
sis [68,69]. Although MCT is widely applied also over longer periods
of time there are no observations and neither short- nor long-term
studies on the effects of MCT in patients with regard to glucose ho-
meostasis and insulin resistance. Our results suggest a need to takeinto consideration that the sex-speciﬁc response to long-term MCT
intake may be of relevance when patients with mitochondrial fatty
acid β-oxidation defects are treated long-term.
4.1. Conclusions
In summary, we here show that the long-term application of anMCT
diet deeply disturbs glucose homeostasis in a sex-speciﬁc manner
resulting in a severe metabolic syndrome in female VLCAD−/− mice.
In particular, the protective effects of estrogens seem to be inhibited
1449S. Tucci et al. / Biochimica et Biophysica Acta 1852 (2015) 1442–1450already during their reproductive period. The highly saturatedMCT diet
associatedwith a lower hepatic stearoyl-CoA desaturase 1 (SCD1) activ-
ity in females exaggerates the harmful effects of anMCTdiet. Themolec-
ular mechanism behind this sex-speciﬁc metabolic response to MCT
needs to be elucidated. More important, the relevance of these ﬁndings
for humans under these dietary modiﬁcations needs to be investigated.
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